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The objectives were to review available PK models for saturable FcRn-mediated IgG disposition, and to explore an alternative
semimechanistic model. Most available empirical and mechanistic PK models assumed equal IgG concentrations in plasma and
endosome in addition to other model-speciﬁc assumptions. These might have led to inappropriate parameter estimates and
model interpretations. Some physiologically based PK (PBPK) models included FcRn-mediated IgG recycling. The nature of
PBPK models requires borrowing parameter values from literature, and subtle diﬀerences in the assumptions may render dramatic
changes in parameter estimates related to the IgG recycling kinetics. These models might have been unnecessarily complicated to
address FcRn saturation and nonlinear IgG PK especially in the IVIG setting. A simple semimechanistic PK model (cutoﬀ model)
wasdevelopedthatassumedaconstantendogenousIgGproductionrateandasaturableFcRn-bindingcapacity.TheFcRn-binding
capacity was deﬁned as MAX, and IgG concentrations exceeding MAX in endosome resulted in lysosomal degradation. The model
parameters were estimated using simulated data from previously published models. The cutoﬀ model adequately described the rat
and mouse IgG PK data simulated from published models and allowed reasonable estimation of endogenous IgG turnover rates.
1.Introduction
Under physiological conditions, IgG has prolonged half-life
(t1/2) relativeto otherplasma proteins, whileIgGelimination
is faster at much higher concentrations. These observations
prompted Brambell et al. to propose a theoretical saturable
protective Fc receptor in 1964 [1]. Subsequently, Brambell
demonstrated that a neonatal intestinal receptor (FcRn)
is responsible for maternal-to-infant IgG transport [2].
Waldmann and Strober later showed that FcRn preferentially
binds to IgG Fc at lower pH [3]. The expression of FcRn
in neonatal gut is transient [4], while in adults FcRn is
expressed primarily in muscle, skin, vascular endothelium at
relativelyhighlevels[5–8].TheFcRn-mediatedIgGrecycling
can be described as a 3-step process: (1) passive pinocytosis
ofIgGintoendothelialcells;(2)acidiﬁcationinendosomeby
H+ ATPase to approximately pH 6 allowing IgG binding to
FcRn; (3) unbound IgG is destined to lysosomal degradation
while bound IgG is diverted back to circulation. Fc-FcRn
binding in endosome may change FcRn distribution and
intracellular traﬃcking of FcRn-coated endosome vesicles
[9]. This directed endosome traﬃcking mechanism may
further explain the high eﬃciency of IgG recycling.
FcRnissimilartotheMHCclassImolecule,consistingof
a three-domain alpha subunit coupled with β-2 microglob-
ulin. Mutation of the FcRn β-2 microglobulin in mice
(β2m −/−) led to approximately 8–15-fold increase in IgG
clearance [4, 6, 10]. This more-than-8-fold lower IgG clear-
ance due to FcRn protection implies that an IgG molecule
undergoes multiple cycles of FcRn-mediated endosomal
recycling before its degradation in lysosome in mice.
Quantitative understanding of IgG recycling has been
evolving.Theﬁrstattemptsinthe1960sbyBrambelletal.[1]
andWaldmannandStrober[3]wereempiricalbycorrelating
fraction catabolic rate with plasma IgG concentrations. In
1966, Wochner et al. studied IgG disposition in patients
with myotonic dystrophy, a hereditary error resulting in
plasma deﬁciency of IgG but not albumin [11]. In 1990,
Waldmann and Terru published IgG disposition in two
patients with familial hypercatabolic hypoproteinemia [12].
These data provided insightful human kinetic data of the
impact of FcRn on IgG disposition. In 2006, Kim et al.
developed a mechanistic PK model for FcRn-mediated IgG
PK in human [13]. The paper was an elegant review of
available quantitative human IgG data in this ﬁeld; it was2 Journal of Biomedicine and Biotechnology
also the ﬁrst attempt to quantitatively assess IgG homeostasis
and its disturbance by genetic FcRn diseases. Despite the
several identiﬁed gaps due to limited available experimental
data [14], the proposed model seems to be so far the best
mechanistic model in human.
Saturation of FcRn by intravenous administration of
highdosesofpooledimmunoglobulin(IVIG)hasbeenasuc-
cessful approach to clear pathogenic autoimmune antibodies
from circulation, especially in patients with immune throm-
bocytopenia (ITP) [15]. Several semimechanistic models
have been proposed to describe IgG disposition in IVIG set-
ting in experimental animal models [16–19]. These models
are discussed in detail in this paper. Quantitative models in
clinical IVIG settings have not been published.
In addition, physiologically based PK (PBPK) models
have been developed [20–23]. The models included multiple
organs/tissues of interest, investigated the kinetics and deter-
minants of IgG tissue distribution, and allowed studying the
nonlinear FcRn and IgG recycling kinetics. However, these
models are complicated in nature, and interpretations of
FcRn-mediated IgG recycling seem very diﬀerent among the
models.
A new semimechanistic PK model is proposed. In
this model, the saturable FcRn binding in endosome and
subsequent IgG degradation are captured using a simple
cutoﬀ approach. The model avoided several questionable
a s s u m p t i o n si np r evi o u sw o rka n da d e q u a t e l yd e s c ri b e dd a t a
simulated from a previously published rat and mouse IVIG
model.
2. Methods
2.1. Source IgG PK Data for Model Fitting. The rat and
mouse semimechanistic IgG PK models [24] developed by
Hansen and Balthasar were reconstructed in NONMEM
(version 6.2.0; Icon Development Solutions, Ellicott City,
MD). Since Hansen’s model was derived from [17, 25]a n d
adequately described [24] the experimental data, Hansen’s
models were used to simulate (reconstruct) the rat and
mouse PK data according to the designs of the original
experiments. Intersubject variability was ﬁxed to 0. The
simulated data were then used as source data to estimate the
PK parameters in the new proposed rat and mouse cutoﬀ
models.
T h er a te x p e r i m e n t a ld e s i g n sw e r ea sf o l l o w s .I nS t u d y
1, an IV bolus dose of a monoclonal antibody 7E3, a
platelet-binding antibody, was given to rats at 0.8, 4, or
8mg/kg. Plasma PK was determined at 1, 3, 6, 12, 24, 48,
72, 96, and 168 hours after dose. In Study 2, rats received
a single high dose IVIG at 0.4, 1, or 2g/kg, followed by
a single IV bolus dose of 7E3 at 8mg/kg. Plasma PK was
determined at 1, 3, 6, 12, 24, 48, 96, and 168 hours after dose.
The simulated PK proﬁles using the reconstructed Hansen’s
model looked identical to the published results [24]. Both
7E3 and endogenous IgG concentration-time proﬁles were
simulated, but only the plasma 7E3 PK data was used to
estimate the parameter values of the new models.
The mouse study was as follows: an IV bolus dose of 7E3
was given to FcRn wild-type (WT) mice with or without
concomitant dosing of 1g/kg IVIG. PK plasma samples were
collected at 1 and 12 hour, and 1, 2, 4, 7, 14, 23, 30, and 60
days after dose. Similarly, an IV bolus dose of 7E3 was given
to FcRn knockout (KO) mice with or without concomitant
dosing of 1g/kg IVIG. PK plasma samples were collected at 1
and 12 hour, and 1, 2, 3, and 4 days after dose. Note that the
mouse PK sampling time points were estimated based on the
published ﬁgures [24] and may be slightly diﬀerent from the
original designs.
2.2. Full Mechanistic PK Model. The concept of the model
is presented in Figure 1. In the full model scheme (upper
panel), IgG disposition involves 3 compartments, that is, a
central (plasma) compartment, a peripheral (tissue) com-
partment, and an endosome compartment nested in the
peripheral compartment. As in Hansen’s paper, IgG of diﬀer-
ent sources (i.e., 7E3, IVIG, and endogenous) were assumed
to follow the same disposition kinetics [24]. In addition
to ﬁrst-order distribution (Q) between the central and
peripheral compartments and ﬁrst-order elimination (CL)
from the central compartment, IgGs in the peripheral com-
partment also undergo endosome circulation/degradation.
This starts with a nonspeciﬁc uptake by pinocytosis of ﬁrst-
order kinetics (CLU), and followed by two transient steps
governed by transit time τ1 and τ2. During τ1, the endosomal
pH decreases to approximately 6 by H+ ATPase in parallel to
IgG sorting when IgG molecules compete for FcRn. During
τ2,unboundIgGsgetdegraded.TheFcRn-boundIgGisthen
recycled to circulation. A convenient assumption was made
that the endosome vesicle volume does not change from the
initial pinocytosis to the ﬁnal fusion to plasma membrane.
This allowed inferring FcRn saturation and fraction of
unbound drug (fU) using the total IgG concentration in the
peripheral compartment. The total volume of endosome at a
given time is determined by CLU and the transit time τ1 and
τ2.
2.3. Reduced Semimechanistic PK Model (Cutoﬀ Model). It
was reported that the endosome transit time is about 7min
[26, 27]. The whole recycling cycle can be instantaneously
compared with the relatively slow elimination phase. For
this reason, a simpliﬁed model was proposed where the
endosome process collapsed into a nonlinear elimination
directly from the peripheral compartment, that is, CLU × fU
(Figure 1, lower panel).
The cutoﬀ model has 6 compartments (CMTs). All the
three sources of IgGs (i.e., 7E3, IVIG, and endogenous IgGs)
were incorporated in the model and share the same PK
parameters including CL, Q,C L U, the central compartment
volume (VC = V1 = V3 = V5), and the peripheral
compartment volume (VP = V2 = V4 = V6). In addition,
it was assumed that kin is the same regardless of the FcRn
status in mice.
Ak e ya s s u m p t i o nw a sm a d ef o rt h efU calculation. A
hypothetical FcRn capacity parameter (Max) was proposed,
fU = (CP,T − Max)/CP,T,w h e r eCP,T is the total IgG
concentration in the peripheral compartments (CMTs 2,
4, and 6). When CP,T ≤ Max, fU = 0. In FcRn KOJournal of Biomedicine and Biotechnology 3
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Figure 1: The proposed cutoﬀ PK models. The full physiological
modelscheme(upperpanel)describesphysicalprocesses,including
IgG distribution in central, peripheral, and endosome compart-
ments, nonspeciﬁc elimination from central compartment (CL),
andFcRn-mediatedendosomalIgGrecyclingandeliminationinthe
endosome. The endosome space is nested in the peripheral com-
partment. In the reduced cutoﬀ PK model scheme (lower panel),
the endosome compartment is collapsed. The net endosomal IgG
clearance isdetermined by endosomal uptake clearance (CLU)f r o m
theperipheralcompartment,theFcRncapacity(Max),thetotalIgG
concentration in peripheral compartment (CP,T), and the unbound
fraction (fU), where fU = (CP,T − Max)/CP,T if CP,T > Max; fU = 0
if CP,T < M a xo ri nF c R nK Om i c e .
mice (i.e., MAX = 0), fU = 1. It was assumed that 7E3,
IVIG, and endogenous IgGs have similar binding aﬃnity for
FcRn. In addition, instead of assuming that the microrate
constants for endosome uptake (kup)a n dr e t u r nr a t e( kret)
are equal as in other semimechanistic models [13, 16–
19], a constant intercompartment clearance was assumed
where the pinocytosis uptake clearance (CLU) is the sum
of endosome degradation clearance (CLU × fU) and the
returning clearance (CLU ×(1 − fU)).
The baseline endogenous plasma IgG concentrations
in FcRn WT animals (C5,WT,0) were ﬁxed to 103μMa n d
14.7μM for rats and mice, respectively [24], where the
subscript 5 is the compartment number (Figure 1,l o w e r
panel), WT stands for FcRn WT, and 0 represents time 0
(baseline). Since the endosome recycling and elimination
are linked to the peripheral compartments (CMTs 2, 4,
and 6), C6,WT,0 may be lower than C5,WT,0 if fU > 0. As
a result, conditional equations were derived to calculate
secondary parameters, including C6,WT,0, the endogenous
IgG production rate (kin), and baseline fU (fU,WT,0)
C6,WT,0 =
C5,WT,0 ×Q +C L U ×MAX
Q +CL U
,( 1 )
kin = C5,.WT,0 × CL + CLU ×C6,WT,0 −CLU ×MAX, (2)
fU,WT,0 =
C6,WT,0 −MAX
C6,WT,0
. (3)
However, when C6,WT,0 ≤ MAX,
C6,WT,0 = C5,WT,0,( 4 )
kin = C5,WT,0 ×CL, (5)
fU,WT,0 = 0. (6)
Note that (1)–(6) rely on the C5,WT,0 values reported in
the literature with normal FcRn expressions. In order to
allow the model to predict endogenous IgG levels in FcRn
KO mice, baseline endogenous IgG levels need to be deﬁned
independent of C5,WT,0
A6,0= VP×
kin×Q +C L U×CL × MAX+CLU× Q ×MAX
Q ×CL + CLU×CL + CLU×Q
,
(7)
A5,0 = VC ×
kin − CLU ×

A6,0/VP

+C L U ×MAX
CL
, (8)
fU =
A6,0 −MAX × VP
A6,0
,( 9 )
where A5,0 and A6,0 are the endogenous IgG levels at baseline
in the central and peripheral compartment, respectively.
In FcRn KO animals, MAX = 0 and the baseline can be
simpliﬁed to the following:
A6,0 = VP ×
kin ×Q
Q ×CL + CLU × CL + CLU ×Q
, (10)
A5,0 = VC ×
kin −CLU ×

A6,0/VP

CL
, (11)
fU = 1. (12)
When A6,0/VP ≤ MAX, there is no IgG elimination from
the peripheral compartment, and the baseline condition is
deﬁned as follows:
A6,0 = VP ×
kin
CL
,
A5,0 = VC ×
kin
CL
,
fU = 0.
(13)
The derivations of the above equations are provided in
the appendix.
The PK of 7E3, IVIG, and endogenous IgGs were further
deﬁned by diﬀerential equations:
dA1
dt
=−
CL ×A1
VC
−
Q ×A1
VC
+
Q ×A2
VP
, (14)
dA2
dt
=
Q ×A1
VC
−
Q ×A2
VP
−
CLU × fU ×A2
VP
, (15)4 Journal of Biomedicine and Biotechnology
dA3
dt
=−
CL ×A3
VC
−
Q × A3
VC
+
Q ×A4
VP
, (16)
dA4
dt
=
Q ×A3
VC
−
Q ×A4
VP
−
CLU × fU ×A4
VP
, (17)
dA5
dt
=−
CL ×A5
VC
−
Q ×A5
VC
+
Q ×A6
VP
+kin, (18)
dA6
dt
=
Q ×A5
VC
−
Q ×A6
VP
−
CLU × fU ×A6
VP
, (19)
where CP,T = (A2 + A4 + A6)/VP,a n dfU = (CP,T −
MAX)/CP,T.
2.4. Cutoﬀ Model Parameter Estimation and Simulation. The
models were coded in NONMEM (version 6.2.0) with FOCE
method. A total of 6 model parameters (i.e., VC, VP,C L ,
Max, Q, and CLU) were estimated by ﬁtting the model
with the simulated rat or mouse 7E3 plasma PK data. A
constantcoeﬃcientofvariationerrormodelwasused.Model
performance was assessed visually by diagnostic plots. The
model was then used to simulate 7E3, IVIG, and endogenous
IgG concentrations under the experimental conditions. A
sensitivity test was conducted to assess the eﬀects of Max and
CLU onthe7E3PKproﬁleinthepresenceorabsenceofIVIG
(2g/kg) using the rat model.
3. Results
The parameter estimates of the reduced models are summa-
rized in Table 1.
The rat cutoﬀ model adequately described the simulated
plasma 7E3 concentrations with or without IVIG using
Hansen’s model (Figures 2(a) and 2(b)). The estimated
VC and VP values were 39.8 and 29.3mL/kg, respectively,
comparable to typical values for IgG reported in the
literature [27]. The Cutoﬀ Max was estimated to be 108μM
(16.2mg/mL). With the endogenous IgG level of 103μM,
rat FcRn should not be saturated at baseline, that is, fU
= 0. CLU,C L ,a n dQ were estimated to be 2580, 24.5,
and 81.0mL/d/kg, respectively. The high CLU value was
somewhatunexpected, but physiologically it may make sense
because a big component of the empirical peripheral com-
partment is comprised of endothelial cells expressing FcRn.
As schematically shown in Figure 1, the nested structure
and the fast CLU suggest high intracompartment traﬃcking
rate and endosomal recycling rate. Since FcRn was not
saturated at baseline, the zero-order kin was estimated to
be 2.52μmol/d/kg (or 378μg/d/kg) using (5) instead of (2).
All disposition PK parameters were estimated with good
precisions (%RSE ≤ 6.7%). However, cautions should be
used in interpreting the %RSE values because of the use of
simulated data in the model ﬁtting.
The plasma and peripheral concentration proﬁles of
7E3, IVIG, and endogenous IgGs were simulated using
the rat cutoﬀ model (Figure 3). Similar to plasma 7E3 PK
proﬁles, the peripheral 7E3 exposures were lower with the
increasing IVIG. The IVIG exposures increased at higher
dose levels, with the highest plasma IVIG IgG concen-
tration of 336μM following 2g/kg IVIG, approximately
3.3 times the endogenous level. This increased the total
IgG concentration above MAX and was the driver for the
nonlinear 7E3 PK. The endogenous IgG PK was minimally
impacted by 7E3 alone (8mg/kg), but decreased follow-
ing IVIG treatment in an IVIG-dose-dependent manner,
reaching maximum suppression of 13%, 28%, and 42%
with 0.4, 1, and 2g/kg IVIG, respectively. The extent of
endogenous IgG suppression was similar to the values
estimated using Hansen’s model (diﬀerences within ±2%)
[24].
Similarly, the mouse cutoﬀ model adequately described
the simulated plasma 7E3 concentrations using Hansen’s
model (Figure 2(c)), with or without IVIG, and in FcRn
WT or KO mice. The estimated VC and VP values were
66.8 and 65.5mL/kg, respectively, larger than the estimates
in the rat cutoﬀ model. The CLU,C L ,a n dQ values were
564, 5.63, and 72.1mL/d/kg, respectively, similar to the
rat estimates. FcRn was not expected to be saturated at
the baseline as MAX was estimated to be 20.1μM, higher
than the mouse baseline endogenous IgG concentration
of 14.7μM. Consistent with Hansen’s model, the levels of
7E3 were eliminated monoexponentially in FcRn KO mice
regardless of IVIG dose as IgGs were no longer protected
by FcRn (Figure 2(c)). The endogenous IgG production rate
was estimated to be 0.0827μmol/d/kg. All PK parameters
were estimated with reasonable precisions except Q that had
a %RSE of 29.8% (Table 1).
The mouse cutoﬀ model was then used to simulate the
plasma and peripheral concentration proﬁles of 7E3, IVIG,
and endogenous IgG under the experimental conditions
(Figure 4). Similar to plasma 7E3 PK proﬁles, the peripheral
7E3 exposures were lower with IVIG in FcRn WT mice.
The highest plasma IVIG IgG concentration following 1g/kg
IVIG was approximately 100μM (7.8 times the endogenous
level),thustransientlydecreasedtheendogenousIgGlevelby
up to 62%. In FcRn KO mice, IgG is not protected by FcRn
(MAX = 0a n dfU = 1) while kin remained the same as in
FcRnWTmice.Asaresult,theplasmaendogenousIgGlevels
at the baseline were 14.7 and 1.19μMi nW Ta n dK Om i c e ,
respectively.
Sensitivity test was conducted with the rat model to
evaluate the eﬀects of Max and CLU on plasma 7E3. In
the absence of IVIG, the plasma 7E3 level increased with
increasing Max when Max was less than total IgG level, but
remained superimposable as Max was ≥108μMa n dfU = 0
(Figure 5). Concomitant 2g/kg IVIG potentiated the eﬀect
of Max, and plasma 7E3 levels increased with the increasing
Max throughout the tested Max range. On the other hand,
changes in CLU did not show appreciable impact on 7E3
PK proﬁles (data not shown), indicating that CLU could not
be well estimated. This is consistent with the higher %RSE
values for CLU in both species (Table 1) and is likely due to
lack of informative data about endosomal IgG elimination
kinetics.Journal of Biomedicine and Biotechnology 5
Table 1: Summary of the cutoﬀ PK model parameter estimates in rats and mice based on the PK data simulated by using Hansen’s PK
models.
Parameter Rat Mouse
Estimate %RSE Estimate %RSE
VC (mL/kg) 39.8 0.563% 66.8 1.46%
Max (μM) 108 0.0756% 20.1 0.557%
Q (mL/d/kg) 81.0 0.519% 72.1 3.47%
CLU (mL/d/kg) 2580 6.7% 564 29.8%
VP (mL/kg) 29.3 0.594% 65.5 7.43%
CL (mL/d/kg) 24.5 0.420% 5.63 12.5%
C0 (μM) 103 (ﬁxed) — 14.7 (ﬁxed) —
EPS 0.000302 43.7% 0.00289 68.5%
In the mouse model, the MAX estimate is for FcRn WT mice; MAX is 0 in FcRn KO mice.
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Figure 2: Cutoﬀ model ﬁtting of plasma 7E3 PK data that were simulated using Hansen’s models. (a) Rat 7E3 PK data ﬁtting at indicated
dose levels without IVIG. (b) Rat 7E3 PK data ﬁtting when 8mg/kg 7E3 were dosed concomitant with IVIG of indicated dose levels. (c)
Mouse 7E3 PK data ﬁtting when 8mg/kg 7E3 was given to FcRn WT or KO mice, with or without 1g/kg IVIG.6 Journal of Biomedicine and Biotechnology
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Figure 3: Simulated PK proﬁles using the rat cutoﬀ model. All rats receive 8mg/kg 7E3, as well as IVIG at indicated dose levels. Plasma and
peripheral concentrations of 7E3, IVIG IgG, and endogenous IgG are plotted.
In most published models, the FcRn-IgG binding and
FcRn saturation were based on either multiexponent func-
tions [1, 3, 20], Langmuir-type binding isotherm, and
quadratic equation solution of unbound concentration [16,
19, 24], or Michaelis-Menten kinetics [13]. In this proposed
model,asimpliﬁedcutoﬀconceptwasintroducedtodescribe
the saturable FcRn-mediated kinetics. The relationship
between the model estimated fU and total peripheral IgG
concentration is plotted in Figure 6. Under the simulated
experimental conditions, the fU r a n g e df r o m0t o0 . 0 7 6i n
rats, 0 to 0.25 in FcRn WT mice, and remained 1 in FcRn
KO mice. For both species (FcRn WT), the cutoﬀ model esti-
mated fU-total peripheral IgG concentration proﬁles are in
parallel with the fU-total plasma IgG concentration proﬁles
estimated using Hansen’s models. The diﬀerence is largely
due to the diﬀerent model structures and the additional
nonspeciﬁc linear IgG elimination (CL) in the cutoﬀ models
which is absent in Hansen’s models.
4. Discussion
4.1. Bleeker’s Model [28]. The relationship between fraction
clearance rate (FCR) and plasma IgG concentration was
described by exponential equations in both human and
mice using previously published data. This approach was
empirical and did not allow physiological interpretation
such as recycling rate and eﬃciency [13]. A mammillary
PK model coupled with the predicted FCR was used for
simulationandtheresultswereconsistentwithIgGt1/2 under
physiological conditions and some clinical data. However,
it underestimated IVIG eﬀect on autoantibody suppression
and overpredicted IgG exposures in FcRn KO model [18].Journal of Biomedicine and Biotechnology 7
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Figure 4: Simulated PK proﬁles using the mouse cutoﬀ model. All mice receive 8mg/kg 7E3 with or without concomitant 1g/kg IVIG in
either FcRn WT or KO mice. Plasma and peripheral concentrations of 7E3, IVIG IgG, and endogenous IgG are plotted.
4.2. Hansen’s Model [24]. The model was comprised of
the central and endosomal compartments (Figure 7(a)).
It considered endogenous IgG, autoantibody (7E3), and
IVIG simultaneously. The strengths of the model include
simplicity, mechanistic basis, and ability to adapt to diﬀerent
situations. The model adequately described 7E3 PK data in
normal and FcRn KO mice, and 7E3 PK data in rats with
or without IVIG. The model was also used to infer the total
FcRn-binding capacity and endogenous IgG turnover rate.
However, the assumption of kup = kret is questionable. At
steady-state in endosome, C1 × kup = CE × kret(1 − fU)+
CE × kdeg × fU. It implied that V1 = VE when the equation
was to be scaled from concentration to amount. This may
not be likely as it was estimated by the same group later
that endosomal space volume is approximately 5mL/kg in
mice[21],muchsmallerthantheplasmavolumeof50mL/kg
[29].
According to Hansen’s model, it appears that the endo-
some compartment has dual functions, that is, to explain the
saturable elimination of IgG and to serve as a distribution
compartment. The PK proﬁles of 7E3 in the absence of IVIG
in the central and the endosome compartments look like
typical 2-compartment PK model [24]. In the presence of
IVIG, the PK proﬁles of 7E3 were lowered due to FcRn
saturation[24].Whileitistheoreticallysoundandpractically
convenient to assume that IgG concentration in the early
endosome is the same as that in the circulation, dual
functions of the endosome compartment had implication on8 Journal of Biomedicine and Biotechnology
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Figure 5: Sensitivity tests for Max. The eﬀect of diﬀerent MAX values on the plasma 7E3 pharmacokinetics was simulated in the presence or
absence of IVIG (2g/kg) using the rat PK model. The tested range was 0.1- to 2-fold the estimated Max (108μM).
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Figure 6: Relationship between fU and total peripheral IgG concentration (cutoﬀ models, solid lines) or total plasma IgG concentration
(Hansen’s models, dashed lines). The fU values for Hansen’s models were calculated according to the published models [4]. The fU values
for the cutoﬀ models were based on the model parameters in Table 1.
the fU estimation. To illustrate this, two sets of fU values
were calculated using the plasma or endosome total IgG
concentrations simulated with Hansen’s model, and plotted
in Figure 8. The signiﬁcant discrepancies and hysteresis
indicate that it may not be appropriate to infer FcRn
saturation using plasma total IgG concentrations under the
particular model assumptions.
In addition, fU was ﬁrst calculated with the total plasma
IgG concentration under the assumption that the total
concentrations in plasma and endosome were the same. On
the other hand, the steady-state endosome IgG concentra-
tion was redeﬁned diﬀerently based on endosomal mass
balance of IgG at steady state. These diﬀerent deﬁnitions
and empirical assumptions reﬂect the lack of informative
experimental data of the endosome compartment and casts
doubt in the interpretation of the model-derived parameter
values. For example, the rat endogenous IgG production rate
was estimated to be 62.9μmol/d/kg in Hansen’s model based
on steady-state condition [24], while it was reported that the
e n d o g e n o u sI g GC Li nr a t si so n l y1 . 9 μmol/d/kg (ranged
f r o m1t o2 . 9μmol/d/kg) following a dose of 131I-labeled rat
IgGs [30].
Since the only mechanism of IgG elimination is through
the endosome pathway (Figure 6(a)) in Hansen’s model, the
total FcRn-binding capacity (Rt) had to be smaller than the
endogenous levels of IgG in order to describe the PK data
(i.e., Rt = 83μM and 12.2μM for mice and rats, resp.)
[24]. In other words, the model structure predeterminedJournal of Biomedicine and Biotechnology 9
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Figure 8: Comparison of fU values derived from IgG concen-
trations in endosome and plasma using Hansen’s rat model after
a single IV dose of 8mg/kg 7E3 in the presence or absence of
IVIG. Signiﬁcant counter clockwise hysteresis was observed due to
IgG distribution delays. In the absence of IVIG, the line visually
collapsed into a short line at the ending point of the counter-
clockwise hysteresis loop as the lack of signiﬁcant change in total
IgG level kept fU relatively constant.
that FcRn had to be saturated at physiological condition.
Furthermore, simulations using the mouse model showed
an accumulation of IgGs in the endosomal compartment in
FcRnKOmice,andthesameendogenousIgGconcentrations
at the baseline between FcRn WT and KO mice (data not
shown). These indicate inappropriate model assumptions,
and cautions should be used when interpreting the modeling
results.
An improved PK/PD model was developed to describe
the IVIG eﬀect on the disposition of MWReg30, an anti-
platelet antibody, and on MWReg30-induced thrombocy-
topenia in mice [16]. The PK model was similar to Hansen’s
model except that the PK data of both MWReg30 and IVIG
were available, and the diﬀerential equations were written
with respect to amounts of MWReg30 and IVIG as opposed
to concentrations in Hansen’s model. This avoided some of
the confusion of distribution volume in Hansen’s model.
However, the diﬀerential equations for endogenous IgGs
were still written with respect to concentration. This was
probably for model simpliﬁcation purpose and due to the
lackofendogenous IgGPKdata.Althoughthishybridmodel
oﬀered some improvement, it was still subject to similar
concerns.
4.3. Xiao’s Model [19]. Another mechanistic FcRn-IgG
model was developed by Xiao et al. recently [19]b a s e do n
total hepcidin and an antihepcidin mAb (Ab 12B9m) con-
centrations (unbound + complex) in cynomolgus monkeys
after single or multiple doses of Ab 12B9m (Figure 7(b)).
Higher clearance of Ab 12B9m was observed after multiple
weekly IV and SC doses of 300mg/kg Ab 12B9m and
was attributed to FcRn saturation. In addition, target-
mediated IgG disposition (TMDD) was incorporated in
order to infer the unbound hepcidin and unbound Ab
12B9m concentrations.10 Journal of Biomedicine and Biotechnology
The model was a modiﬁed version of Hansen’s model
by inheriting the assumption of Langmuir-type FcRn-IgG
interaction and kup = kret. The model had a peripheral
compartment, so that the endosomal compartment did not
have to bear the dual functions as discussed in Hansen’s
model. Because it included unbound Ab 12B9m and its
complex with hepcidin, endogenous IgG was not considered
in the model to minimize the model complexity. As a
result, interpretation of FcRn saturation should be viewed
with caution. Another diﬀerence was that the endosome
compartment volume (VE) was included in the model to
allowabettersenseofmasstransfer.However,theendosomal
volume VE and the dissociation constant kD for FcRn-IgG
binding were estimated as a product rather than separately
since they operated in the model only as a product.
4.4. Kim’s Model [13]. A mechanism-based PK model for
human IgG was developed based on saturable kinetics and
data from the literature using easily measurable plasma
concentrations (Figure 7(c)). This appeared to be the ﬁrst
paper that addressed FcRn-mediated IgG recycling kinetics
quantitatively in human. Note that this model was designed
for endogenous IgG only although it may be adapted for
therapeutic IgG and/or IVIG. All parameter values, with
exception of km, were borrowed from the literature. It was
recognized that the plasma concentration was not identical
too but as an index for endosomal unbound IgG concentra-
tion. In addition, as an improvement from previous models,
kup = kret was no longer assumed.
In this model, the rate constants for IgG internalization,
catabolism, and recycling were deﬁned as kint, kcat,a n dkrmr,
respectively. Because the plasma compartment (V1) and the
endosome compartment (VE) were collapsed as the vascular
space in the simpliﬁed model, the IgG concentrations
became the same (CSS). Although the kint retained its
physiological meaning to describe the IgG catabolism and
traﬃcking within vascular space, that is, kint = kcat + krmr,
according to equations Jrmr = Jmax × CSS/(km + CSS)a n d
Jcat = kcat ×Css ×V1, the recycling rate Jrmr and the catabolic
rate Jcat were directly linked to the vascular space, and no
longer rely on kint despite of the sequential events as shown
in the model scheme (Figure 7(c)). As a result, kint is not
kinetically informed by other processes in the model, and
obtaining kint value solely relied on the literature. This might
be a problem especially when the values of most parameters
were borrowed from literature where diﬀerent physiological
and/or mechanistic assumptions might have been made.
Probably because of this, the model did not seem to be able
to explain the high fractional catabolic rate of IgG in patients
with familial hypercatabolic hypoproteinemia.
In addition, as the author pointed out, the estimated
rate of pinocytosis (kup) was smaller in magnitude than the
real unidirectional uptake rate, so the daily fractional uptake
rate (18%), the fractional recycling rate (10.6%), and the
fraction catabolic rate (7.4%) should be interpreted with
cautions. Indeed, the inferred eﬃciency of FcRn-mediated
IgG recycling (∼60%) was lower than what can be inferred
from the IgG PK data from two reported cases of familial
hypercatabolic hypoproteinemia with non-functional FcRn
due to a mutant β2mgene. Inthese patients withnormal IgG
synthesis rates, IgG survival was short. The IgG fractional
catabolic rates increased ﬁvefold to 31% and 36% of the
intravenous pool per day (normal 6.7 ± 2%/d) [12]. This
approximate 5-fold increase in FCR suggested that under
normal physiological conditions, an average IgG molecule is
degraded after approximately 5 times endothelial pinocyto-
sis, or approximately 80% eﬃciency of FcRn-mediated IgG
recycling.
Another diﬀerence between Kim’s model and previously
discussed models was the empirical Emax model for FcRn-
IgG binding. It was equivalent to early regression models by
Brambell and Waldmann [1, 3]. km was deﬁned as the serum
IgG concentration at which a half maximal IgG recycling was
achieved and was estimated to be 21mg/mL. Choosing the
total serum IgG concentration for FcRn-binding estimation
might have been a convenient approximation; however,
cautions should be used when comparing results from
models with diﬀerent structures.
4.5. Physiological Models. Several physiologically based PK
(PBPK) models were developed for anticarcinoembryonic
antigen (CEA) antibodies [20, 22]o r7 E 3[ 21]i nm i c e .
The models included organs/tissues of interest, lymphatic
circulation, FcRn-IgG binding, and IgG-CEA binding (if
applicable). Most physiological parameters regarding plasma
ﬂow rate, vascular, interstitial, and total tissue volume were
available from the literature. Lymphatic circulation rate
was either assumed [21] or estimated [20, 22]. Endosome
update and return rates were either ﬁxed to be the same
value [22] or estimated [20, 21]. In general, the models
described/predicted the anti-CEA antibody PK reasonably
well. However, depending on the model assumptions, the
FcRn or endosome-related parameter values might be very
diﬀerent. For example, Ferl’s estimations of kint and krec
were 1.38 day−1 and 0.5 day−1,r e s p e c t i v e l y[ 20], while
in Garg’s model, the values were 1.96 day−1 and 20.4
day−1,r e s p e c t i v e l y[ 21, 24]. In a recent revision of the
model, target-mediated disposition was included in addi-
tion to the FcRn-IgG binding, where kint and krec were
assumed to be the same and estimated to be 0.715 day−1
[22]. In addition, the percentage and mechanism of IgG
elimination in each organ were interpreted diﬀerently.
According to Ferl’s model, approximately 40% of IgG
eliminated was attributed to linear elimination kinetics
in liver and other organs, while in Garg’s model, skin,
muscle, liver, and gut were the major organs responsible
for 33, 24, 16, and 12% of total IgG elimination, respec-
tively.
It is well recognized that the PBPK models have the
potential to better describe the physiological processes, and
thus may allow more meaningful interpretations. On the
other hand, it should be noted that these models usually
have complicated structures and heavily depend on available
data from the literature. The complexity as an eﬀort to best
describe the physiological processes came with the need for
more sophisticated modeling assumptions. Multiplicity ofJournal of Biomedicine and Biotechnology 11
assumptions and potential error prorogation may lead to
liabilities to model misspeciﬁcation and result in misinter-
pretation.Theroutinelyperformed“modelvalidation”using
a small experimental data set might not be suﬃcient for
model testing and assumption justiﬁcation, as the inherent
model ﬂexibility may sometimes allow apparent good data
ﬁtting even when some inappropriate assumptions were
made.
4.6. The Proposed Semimechanistic Cutoﬀ Model. It has been
reported that some IgGs with higher aﬃnity for FcRn
showed prolonged t1/2 [31, 32]. However, aﬃnity for FcRn
may not be the only major contributor to IgG catabolic
rate [33]. Physiological PK models have been proposed,
including the one in Figure 1(a), to depict the saturable
FcRn-mediated IgG kinetics based on known physiology.
However, in a strict sense, quantitative physiological models
have not been published. The reason might be twofold.
First, there is insuﬃcient understanding of the intracellular
events and diﬃculty in scaling data from in vitro to in vivo
(e.g., volume, rate, and transit time). In addition, there is
insuﬃcient or uninformative in vivo PK data to develop
and diﬀerentiate such PK models. The simulated data using
Hansen’s model was easily described by the new cutoﬀ
model. The model parameters were estimated fairly precisely
(Table 1). However, other models with diﬀerent structural
assumptions might be able to describe the data equally well.
To better test a model, additional PK data are required, for
example, PK of total IgG.
It is fair to say that none of the available models (includ-
ing the cutoﬀ model) adequately mimicked the physiology
of FcRn-mediated IgG recycling, and more sophisticated
physiological models cannot be developed simply because
the lack of informative experimental data in the endosome
compartment. For example, the rate of pinocytosis at a
whole body level is diﬃcult to measure experimentally.
In addition, although the mean transit time of endosome
was inferred to be about 7min [26, 27], it remains largely
unknown how endosome is destined to lysosome kinetically
and how IgG degradation changes as a function of the
mean transit. For example, it was reported that FcRn-IgG
binding in endosome triggers more eﬃcient intracellular
traﬃcking and transcytosis [9], but the quantitative impact
on the endosomal recycling is not clear. And the dynamics
of pH lowering in early endosome is not easy to describe
mathematically. Furthermore, it was realized that FcRn
saturation estimated based on plasma IgG levels may not
approximate the real situation in endosome as discussed
for Hansen’s model. The technical diﬃculties in estimating
the parameters governing the FcRn-mediated IgG recycling
process prevent developing models that truly resembles the
physiology.
Taken together, it might be practically justiﬁed to utilize
simple models of FcRn-mediated IgG disposition such as the
cutoﬀ model, especially in the IVIG setting, and leave more
sophisticated models for later optimization when cumulative
understanding of this physiological process allows so.
The proposed cutoﬀ model has only 6 parameters
(Table 1). The distribution volume parameters VC and VP
were clearly deﬁned. The collapsed IgG recycling was based
on the relative short endosome mean transit time, and the
assumption that FcRn-IgG dissociation did not happen, or
more appropriately, only happened to a constant extent. It
allows estimation of nonspeciﬁc linear CL and nonlinear
endosomal elimination. At baseline level in both rats and
FcRnWTmice,thelinearCLaccountedfor100%ofendoge-
nous IgG elimination. The apparent nonspeciﬁc linear CL
at baseline should be further discussed. Mathematically, CL
accounted for the linear portion of IgG elimination, but
it did not necessarily imply endosome-unrelated processes.
For example, a fraction of IgG in endosome could end
up in the lysosome degradation pathway even when FcRn
is not saturated. This is possible considering variability in
the biological processes such as the endosome acidiﬁcation
dynamics, transit time of endosome intracellular traﬃcking,
andconversiontolysosome,aswellasproteolysiskinetics. At
a whole-body level, the above could have led to an apparent
nonspeciﬁclinear.Itisalsoimportanttorealizethatalthough
s e v e r a lo r g a n sa n dt i s s u e sh a v eb e e ni d e n t i ﬁ e dt oe x p r e s s
FcRn, the expression levels may be diﬀerent. It has been
reported that the dispersed pinocytotic activities of virtually
all cells capture and process all soluble plasma proteins at a
rate of ≈2x per day with equivalent degradative rates unless
t h e ya r ep r o t e c t e db ys p e c i ﬁ cm e c h a n i s m s[ 4]. This high
pinocytosis rate not only explains the nonspeciﬁc linear CL,
butalsoisconsistentwiththehighCLU valuesinbothspecies
estimated by the cutoﬀ models (Table 1).
In rats, the estimated production rate of endogenous
IgGs in rats was 2.52μmol/d/kg using the cutoﬀ model,
slightlylowerthanthemeasuredvalueof1.9μmol/d/kg(ran-
ged 1 to 2.9μmol/d/kg) [30]. In FcRn WT mice, the endoge-
nous production rate was estimated to be 0.0827μmol/d/kg,
lower than previously reported value 0.132μmol/d/day
(assumed 50mL/kg plasma) [4, 34]. Apparently, there is
room for further model improvement and more precise
parameter estimation (e.g., CLU) with emerging experimen-
taldataandbetterunderstandingofthephysiology.However,
it is important to note there has been a big improvement
from in the previous model [24], where the kin estimates
were 62.9 and 1.21μmol/d/kg in rats and FcRn WT mice,
respectively.
Diﬀerent plasma endogenous IgG levels were reported
between rats (103μM) and mice (14.7μM) at the baseline
[24]. According to the cutoﬀ model results, FcRn was almost
saturated in rats (MAX = 108μM) at the baseline but not
in FcRn WT mice (MAX = 20.1μM). In addition, rats
seemed to have higher CL and CLU than mice according to
the cutoﬀ models (Table 1). These diﬀerences translated to
an estimated 30-fold faster kin in rats than in mice versus
approximately a 14-fold diﬀerence reported in the literature
[4, 30, 34]. Further investigation would help understand the
between-species diﬀerence in endogenous IgG turnover.
According to the cutoﬀ model, FcRn should not be
saturated at baseline, and the baseline total IgG clearance
was determined solely by the nonspeciﬁc linear CL. The
total body IgG clearance started to increase when the total
peripheral IgG concentration exceeded MAX. In both rats
and FcRn WT mice, the 7E3 plasma exposure decreased with12 Journal of Biomedicine and Biotechnology
the concomitant IVIG (Figures 2(b) and 2(c)). This is diﬀer-
ent from Hansen’s model which predicted FcRn saturation
at the baseline [24]. In addition, the mouse cutoﬀ model
is able to predict the endogenous IgG concentrations for
FcRn WT and KO mice. The estimated baseline endogenous
IgG concentrations in plasma were estimated to be 14.7 and
1.19μM for FcRn WT and KO mice, respectively. This 12-
fold decrease in the baseline IgG level reﬂects accelerated IgG
catabolism in the absence of FcRn, consistent with reported
values of 8–15-fold [4, 6, 10]. On the other hand, Hansen’s
model infers that the baseline endogenous IgG level remains
the same in FcRn WT and KO mice [24].
In conclusion, A simple cutoﬀ model was proposed
for IgG PK modeling with saturable FcRn-mediated IgG
disposition in rats and mice.
Appendix
DetailedDerivationof Equations
(1) Derivation of secondary PK parameters with the baseline
plasma endogenous IgG concentration in rats and FcRn WT
mice.
Based on mass balance of endogenous IgGs between
CMT5 and CMT6, C5,WT,0 × Q = C6,WT,0 × Q + C6,WT,0 ×
CLU × fU,w h e r efU = (C6,WT,0 −MAX)/C6,WT,0.
SoC5,WT,0×Q = C6,WT,0×Q+CLU×(C6,WT,0−MAX),
If C6,WT,0 > MAX,
thenC6,WT,0 = (C5,WT,0×Q+CLU ×MAX)/(Q+CLU)
and fU,WT,0 = (C6,WT,0 −MAX)/C6,WT,0
If C6,WT,0 ≤ MAX, then C6,WT,0 = C5,WT,0 and
fU,WT,0 = 0.
For endogenous IgGs at baseline, production rate = eli-
mination rate,
kin = C5,WT,0 ×CL +C6,WT,0 ×CLU × fU. (A.1)
If C6,WT,0 > MAX, kin = C5,WT,0 × CL + CLU ×
(C6,WT,0 −MAX);
If C6,WT,0 ≤ MAX, kin = C5,WT,0 × CL.
(2) Derivation of baseline endogenous IgG levels. The
key is to allow model prediction of baseline plasma and
peripheral IgG levels in both FcRn WT and KO animals.
With mass balance at baseline,
kin =
A5,0
VC
×CL +
A6,0
VP
×CLU × fU,
A5,0
VC
×Q =
A6,0
VP
×Q +
A6,0
VP
×CLU × fU,
(A.2)
Solve the above equations for A5,0/VC and A6,0/VP,
A6,0
VP
=
kin ×Q
Q × CL + CLU ×CL ×

A6,0/VP −MAX

/

A6,0/VP

+C L U ×Q ×

A6,0/VP −MAX

/

A6,0/VP
. (A.3)
If A6,0/VP > MAX,
then A6,0/VP = (kin ×Q+CL U ×CL×MAX+CLU ×
Q ×MAX)/(Q ×CL + CLU ×CL + CLU ×Q),
and A5,0/VC = (kin −CLU ×(A6,0/VP −MAX))/CL.
If A6,0/VP ≤ MAX,
then A6,0/VP = kin × Q/(Q ×CL) = kin/CL,
and A5,0/VC = kin/CL.
In FcRn KO mice, A6,0/VP and A5,0/VC do not need to be
separatelycoded.Instead,anNONMEMinputdataentryhas
FCRN = 0 for KO mice or FCRN = 1f o rW Tm i c e .M A Xi s
deﬁned as MAX0× FCRN, where MAX0 is the MAX in FcRn
WT mice. So MAX =0forK Omic e,andA6,0/VP andA5,0/VC
equations can be simpliﬁed as
A6,0
VP
=
kin ×Q
Q ×CL + CLU ×CL +CLU ×Q
,( A . 4 )
A5,0
VC
=
kin −CLU ×

A6,0/VP

CL
. (A.5)
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